SAN DIEGO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Trans NewMediaWire – Medical marijuana, Inc. (OTC: MJNA) (“the Company”), the first publicly traded cannabis company in the United States that launched the world’s first cannabis-derived products, brands, and supply chain, today announced its pharmaceutical subsidiary, HM Pharmaa producer of cannabidiol (CBD) products after receiving the health clearance from ANVISA, the Brazilian health regulation agency.
Under the ANVISA 327/2019 standard, this registration allows companies such as HM Pharma to import large quantities of raw extracts, isolate cannabinoids or finished products as well as manufacture and distribute cannabis products to pharmacies in Brazil.
“This is a great achievement for our company and great news for the citizens of Brazil,” said Matheus Batelli, Managing Director of HM Pharma. “The submission of our file is the final step to register our product as a pharmaceutical product in Brazil to enable our company to sell our products in pharmacies. We hope to provide another option for accessing CBD for those in need.”
Medical Marijuana, Inc. HempMeds® Brasil subsidiary was the first company to legally import products into Brazil in 2015 using Brazil’s compassionate use laws. The compassionate use market is booming in Brazil and will continue to co-exist with the medical market. HempMeds® Brasil, which is currently growing 75% faster than the overall Brazilian CBD market and is the leading cannabis player in Brazil, will continue to operate under the compassionate use model, while HM Pharma will operate under ANVISA normative 327/2019.
“It is great to see the continued growth and regulatory progress of our company in Brazil,” said Blake Schroeder, CEO of Medical Marijuana. “We are optimistic about our impressive momentum forward in the pharmaceutical space, and look forward to sharing more exciting updates on our new sales channels in the near future.”
About Medical Marijuana, Inc.
We are Firsts®. Medical marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabis space: a global portfolio of hemp-based nutritional brands led by Kanawee® And HempMeds®; leader in sourcing high quality, legal, non-psychoactive cannabis products derived from industrial hemp; and the cannabis-based clinical research and plant-based drug development segment led by pharmaceutical investment firms and their partners incl AXIM® Biotechnologies, Inc. And Neurobatics. Medical Marijuana, Inc. As the best CBD product by CNBC. Medical Marijuana, Inc. Also the first company to obtain historical import authorizations for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in the development of international markets. The company’s main product Real scientific hemp oil It has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc. is headquartered in In San Diego, California, additional information is available at OTCMarkets.com or by visitingwww.medicalmarijuanainc.com. Watch the Medical Marijuana, Inc. video. , click here.
Forward-looking Disclaimer
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, and is subject to the safe harbor laws established by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and are subject to risks and uncertainties. These forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to differ. materially from the data presented here.
Disclosure to the Food and Drug Administration (FDA)
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Legal disclosure
Medical Marijuana, Inc. does not sell or distribute any products that violate the US Controlled Substances Act.
communication:
PR contact:
Kyle Porter
CMW Media
pp. 858-221-8001
[email protected]
www.cmwmedia.com
Investor Relations Contact:
P. (858) 283-4016
[email protected]
